Nordicus Partners (NORD) 10-Q 12 Feb 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	9 Months Ended
	Dec. 31, 2015	Sep. 30, 2015
Document and Entity Information:
Entity Registrant Name	Advansource Biomaterials Corp
Document Type	10-Q
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Entity Central Index Key	1,011,060
Current Fiscal Year End Date	--03-31
Entity Common Stock, Shares Outstanding	21,490,621
Entity Public Float		$ 2,532,270
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Trading Symbol	asnb

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015		Mar. 31, 2015
Current assets
Cash	$ 231		$ 75
Accounts receivable-trade, net	166	[1]	214	[2]
Accounts receivable-other	113		76
Inventories, net	242		304
Prepaid expenses and other current assets	5		6
Total current assets	757		675
Property, plant and equipment, net	1,936		1,998
Deferred financing costs, net	75		80
Other assets	47		47
Total assets	2,815		2,800
Current liabilities
Accounts payable	186		295
Accrued expenses	173		362
Customer advance	11		77
Notes payable			50
Capital lease obligation	3		8
Deferred revenue	25		43
Total current liabilities	398		835
Long-term liabilities
Long-term financing obligation	1,986		1,986
Accrued interest on financing obligation	156		147
Total long-term liabilities	2,142		2,133
Total liabilities	$ 2,540		$ 2,968
Commitments and contingencies
Stockholders' equity
Preferred stock		[3]		[4]
Common stock	$ 21	[5]	$ 21	[6]
Additional paid-in capital	38,097		38,061
Accumulated deficit	(37,813)		(38,220)
Treasury stock	(30)	[7]	(30)	[8]
Total stockholders' equity	275		(168)
Total liabilities and stockholders' equity	$ 2,815		$ 2,800
[1]	Net of allowance of $5 as of 12/31/2015.
[2]	Net of allowance of $5 as 3/31/2015.
[3]	$.001 par value, 5,000,000 shares authorized; no shares issued and outstanding as of 12/31/2015.
[4]	$.001 par value, 5,000,000 shares authorized; no shares issued and outstanding as of 3/31/2015.
[5]	$.001 par value, 50,000,000 shares authorized; 21,567,313 shares issued and 21,490,621 shares outstanding as of 12/31/2015.
[6]	$.001 par value, 50,000,000 shares authorized; 21,567,313 shares issued and 21,490,621 shares outstanding as of 3/31/2015.
[7]	76,692 shares at cost at 12/31/2015.
[8]	76,692 shares at cost at 3/31/2015.

Condensed Statements of Operati

Condensed Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Revenues
Product sales	$ 439	$ 355	$ 2,344	$ 1,020
License, royalty and development fees	153	142	461	652
Total revenues	592	497	2,805	1,672
Cost of sales	242	182	869	620
Gross profit	350	315	1,936	1,052
Operating expenses
Research, development and regulatory	75	84	228	277
Selling, general and administrative	297	325	1,032	981
Total operating expenses	372	409	1,260	1,258
Income (loss) from operations	(22)	(94)	676	(206)
Interest and other expenses
Interest expense	89	91	269	287
Total interest and other expense	89	91	269	287
Net income (loss)	$ (111)	$ (185)	$ 407	$ (493)
Net income (loss) per common share, basic	$ (0.01)	$ (0.01)	$ 0.02	$ (0.02)
Net income (loss) per common share, diluted	$ (0.01)	$ (0.01)	$ 0.02	$ (0.02)
Shares used in computing net income (loss) per common share, basic	21,491	21,491	21,491	21,491
Shares used in computing net income (loss) per common share, diluted	21,491	21,491	22,631	21,491

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities
Net income (loss)	$ 407,000	$ (493,000)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	62,000	105,000
Amoritization of deferred financing costs	5,000	5,000
Provision for inventory reserve		25,000
Stock-based compensation	36,000	9,000
Changes in assets and liabilities:
(Increase) decrease in accounts receivable-trade	48,000	(135,000)
(Increase) decrease in accounts receivable-other	(37,000)	(4,000)
(Increase) decrease in inventories	62,000	(116,000)
(Increase) decrease in prepaid expenses and other current assets	1,000
Increase (decrease) in accounts payable	(109,000)	67,000
Increase (decrease) in accrued expenses	(180,000)	243,000
Increase (decrease) in customer advance	(66,000)	77,000
Increase (decrease) in deferred revenue	(18,000)	(40,000)
Net cash flows provided by (used in) operating activities	211,000	(257,000)
Cash flows from financing activities
Repayment of promissory note	(50,000)
Repayment of capital lease obligation	(5,000)
Net cash flows provided by (used in) financing activities	(55,000)
Net change in cash	156,000	(257,000)
Cash at beginning of period	75,000	268,000
Cash at end of period	231,000	11,000
Supplemental disclosures of cash flow information
Interest paid	$ 254,000	196,000
Purchase of equipment on capital lease		$ 13,000

Description of Business

Description of Business	9 Months Ended
	Dec. 31, 2015
Notes
Description of Business	1. Description of Business AdvanSource Biomaterials Corporation develops advanced polymer materials which provide critical characteristics in the design and development of medical devices. Our biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. Our business model leverages our proprietary materials science technology and manufacturing expertise in order to expand product sales and royalty and license fee income. Our technology, notably products such as ChronoFlex®, HydroMed , and HydroThane , which have been developed to overcome a wide range of design and functional challenges, such as the need for dimensional stability, ease of manufacture and demanding physical properties to overcoming environmental stress cracking and providing heightened lubricity for ease of insertion. Our new product extensions customize proprietary polymers for specific customer applications in a wide range of device categories. Our corporate, development and manufacturing operations are located in our leased facility in Wilmington, Massachusetts.

Interim Financial Statements an

Interim Financial Statements and Basis of Presentation	9 Months Ended
	Dec. 31, 2015
Notes
Interim Financial Statements and Basis of Presentation	2. Interim Financial Statements and Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, these unaudited condensed financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments (consisting only of normal recurring adjustments), which we consider necessary, for a fair presentation of those financial statements. The results of operations and cash flows for the nine months ended December 31, 2015 may not necessarily be indicative of results that may be expected for any succeeding quarter or for the entire fiscal year. The information contained in this quarterly report on Form 10-Q should be read in conjunction with our audited financial statements included in our annual report on Form 10-K, as amended, as of and for the year ended March 31, 2015 as filed with the Securities and Exchange Commission (the “SEC”). Our significant accounting policies are described in Note 2 to the financial statements included in Item 8 of our annual report on Form 10-K as of March 31, 2015. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments, which are evaluated on an ongoing basis, and that affect the amounts reported in our unaudited condensed financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and judgments. In particular, significant estimates and judgments include those related to revenue recognition, allowance for doubtful accounts, inventory reserves, useful lives and valuation of property and equipment.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Dec. 31, 2015
Notes
New Accounting Pronouncements	3. New Accounting Pronouncement We have evaluated all issued but not effective accounting pronouncements and determined that they are either immaterial or not relevant to us.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Dec. 31, 2015
Notes
Related Party Transactions	4. Related Party Transactions On August 22, 2013, Mr. Adams, our Chief Executive Officer, and David Volpe, our former Chief Financial Officer, participated along with three independent investors (collectively, the “Investors”) in an aggregate financing resulting in the issuance of $100,000 in promissory notes (see Note 11). Messrs. Adams and Volpe each contributed approximately $13,000 in cash. In addition to the promissory notes, Messrs. Adams and Volpe also received warrants entitling them to exercise said warrants into 54,375 shares of our common stock at an exercise price of $0.075 per share (see Note 9). As of December 31, 2015 and March 31, 2015, the principle balance of the promissory notes was $0 and $50,000, respectfully and in the aggregate, of which $0 and $12,500, respectfully, was due to Messrs. Adams and Volpe in the aggregate. All warrants issued in connection with this transaction expired on August 21, 2014.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Dec. 31, 2015
Notes
Stock-Based Compensation	5. Equity-Based Compensation Our 1996 Employee, Director and Consultants Stock Option Plan (the “1996 Plan”) was approved by the Board of Directors and Stockholders in March 1996. A total of 7,000,000 shares were reserved for issuance under the 1996 Plan. Under the terms of the 1996 Plan, the exercise price of Incentive Stock Options issued under the 1996 Plan must be equal to the fair market value of the common stock at the date of grant. In the event that Non Qualified Options are granted under the 1996 Plan, the exercise price may be less than the fair market value of the common stock at the time of the grant (but not less than par value). In October 2003, our shareholders approved the 2003 Stock Option Plan (the “2003 Plan”), which authorizes the issuance of 3,000,000 shares of common stock with terms similar to the 1996 Plan. In January 2006, we filed Form S-8 with the SEC registering an additional 489,920 total shares of common stock in the 1996 Plan and 2003 Plan. Total shares of common stock registered under the 1996 Plan and 2003 Plan (collectively, the “Plans”) are 10,489,920. Substantially all of the stock options granted pursuant to the 1996 Plan provide for the acceleration of vesting of the shares of common stock subject to such options in connection with certain changes in our control. A similar provision is not included in the 2003 Plan. Options granted expire ten years from the grant date. As of September 30, 2013, all Plans and shares not granted expired. As of December 31, 2015, there are no other equity incentive plans in place for the future issuance of our common stock. Activity under the Plans for the nine months ended December 31, 2015 is as follows: Options Outstanding Weighted-Average Exercise Price per Share Weighted-Average Remaining Contractual Term in Years Aggregate Intrinsic Value (in thousands) Options outstanding as of April 1, 2015 2,170,750 $ 0.36 $ 190 Granted - - Exercised - - Cancelled or forfeited - - Options outstanding as of December 31, 2015 (unaudited) 2,170,750 $ 0.36 4.71 $ 190 Options exercisable as of December 31, 2015 (unaudited) 2,002,937 $ 0.39 4.46 $ 148 Options vested or expected to vest as of December 31, 2015 (unaudited) 2,170,750 $ 0.36 4.71 $ 190 Our unaudited condensed statements of operations include equity-based compensation expense related to our stock option plans for employee and non-employee director awards in the amount of $2,000 and $2,000 for the three months ended December 31, 2015 and 2014, respectively, and $8,000 and $9,000 for the nine months ended December 31, 2015 and 2014, respectively. There was no income tax benefit related to these costs. As of December 31, 2015, the total amount of unrecognized equity-based compensation expense was approximately $7,000 which will be recognized over a weighted average period of .67 years.

Inventory

Inventory	9 Months Ended
	Dec. 31, 2015
Notes
Inventory	6. Inventories Inventories, net, are stated at the lower of cost (first in, first out) or market and consist of the following: (in thousands) December 31, 2015 (unaudited) March 31, 2015 Raw materials $ 109 $ 80 Work in progress 39 76 Finished goods 224 278 372 434 Less: allowance for obsolete and excess inventory (130) (130) Total inventories, net $ 242 $ 304 During the fiscal year ended March 31, 2015, we allowed a significant customer to return certain polymer products which were sold and shipped in a prior year (the “Returned Goods”) and paid for by the significant customer in a prior year. As a result, the significant customer was issued a sales credit/discount in the amount of the selling price of the polymer products, which was approximately $127,000. We also recorded a sales allowance of approximately $127,000 with respect to the Returned Goods. As a result, the product sales were reduced in our statement of operations for the fiscal year ended March 31, 2015 and the associated liability was included in accrued expenses on the balance sheet at March 31, 2015. The sales credit/discount to this significant customer was applied in full to this customer’s account in connection with the shipment of product during the three months ended June 30, 2015 and the associated liability as of December 31, 2015 is $0. The inventory cost of the Returned Goods was approximately $25,000 and was recorded as an increase to our finished goods inventory as of March 31, 2015. Based on managements’ review of the Returned Goods, we concluded the likelihood of selling a large amount of the Returned Goods within the near term was not determinable. Accordingly, an additional allowance for the excess inventory of approximately $25,000 was recorded as of March 31, 2015. As of December 31, 2015, there have been no sales of the Returned Goods and the related allowance for the excess inventory as of December 31, 2015 is approximately $25,000. We have no history of having allowed for a product return prior to this date and we have not changed our policy for future returns by customers once the customer has accepted delivery of the product.

Property, Plant and Equipment D

Property, Plant and Equipment Disclosure	9 Months Ended
	Dec. 31, 2015
Notes
Property, Plant and Equipment Disclosure	7. Property, Plant and Equipment Property, plant and equipment consists of the following: (in thousands) December 31, 2015 (unaudited) March 31, 2015 Land $ 500 $ 500 Building 2,705 2,705 Machinery, equipment and tooling 1,214 1,214 Furniture, fixtures and office equipment 285 285 Office equipment under capital lease 13 13 4,717 4,717 Less: accumulated depreciation (2,781) (2,719) $ 1,936 $ 1,998 For the three months ended December 31, 2015 and 2014, depreciation expense was $14,000 and $22,000, respectively. For the nine months ended December 31, 2015 and 2014, depreciation expense was $62,000 and $105,000, respectively.

Income (Loss) Per Share

Income (Loss) Per Share	9 Months Ended
	Dec. 31, 2015
Notes
Income (Loss) Per Share	8. Income (Loss) Per Share Basic income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per common share are based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income (loss) that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted income (loss) per share calculations because the effect would be antidilutive or the options exercise prices were greater than the average market price of the common shares, were 3,001,250 shares and 1,499,500 shares for the three and nine months ended December 31, 2015, respectively, and 2,685,048 shares and 2,685,048 shares, for the three and nine months ended December 31, 2014, respectively.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Dec. 31, 2015
Notes
Stockholders' Equity	9. Stockholders’ Equity Common Stock Options and Warrants On July 22, 2015, we engaged the services of a financial and strategic advisor whose services include, but are not limited to, financial advice, strategic advice and investment banking services. In connection with this engagement, we agreed to compensate the investment bankers approximately $4,000 per quarter for a one year period and we issued them a warrant to purchase 830,500 shares of our common stock at an exercise price of $0.0301 per share, the approximate fair value of our common stock on the date of the engagement. The warrant is exercisable at any time until July 21, 2025. The warrant was valued at approximately $28,000 using the Black-Scholes model and was expensed to compensation in the three month period ended September 30, 2015. There were no exercises of options or warrants by employees or consultants during the three and nine months ended December 31, 2015 and 2014, respectively. Employee Stock Purchase Plan There were no shares of our common stock issued pursuant to the Employee Stock Purchase Plan (the “ESP Plan”) as of December 31, 2015 as all 500,000 shares authorized under the ESP Plan have been issued.

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2015
Notes
Income Taxes	10. Income Taxes The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. A valuation allowance has been recorded to offset all deferred tax assets due to uncertainty of realizing the tax benefits of the underlying operating loss and tax credit carry forwards over their carry forward periods. We have no significant deferred tax liabilities as of December 31, 2015 and March 31, 2015. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate this tax position on a quarterly basis. We also accrue for potential interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense. As of December 31, 2015 and March 31, 2015, we had no material unrecognized tax benefits and no adjustments to liabilities or operations were required.

Notes Payable

Notes Payable	9 Months Ended
	Dec. 31, 2015
Notes
Notes Payable	11. Notes Payable On August 22, 2013, we entered into Promissory Notes in the aggregate principal amount of $100,000 (the “Notes”) with three shareholders and our chief executive officer and former chief financial officer (the “Investors”). The Notes had a six-month term, interest at the rate of 1.75% per month and all principal and accrued interest, if any, was due and payable on or before February 21, 2014. In lieu of cash payment of interest, the Investors chose to receive Warrants exercisable into an aggregate 435,000 shares of our common stock. The Warrants had a one-year term and were exercisable at a 150% premium over the closing price of our common stock as of August 21, 2013, or $0.075 per share. The Notes were secured by accounts receivable from certain customers. During the fiscal year ended March 31, 2014, we repaid $50,000 of the principal balance of the Promissory Notes and the principal balance outstanding as of March 31, 2015 was $50,000. During the three months ended June 30, 2015, we repaid the remaining principle balance of $50,000 and accrued interest of approximately $14,000. We have no Promissory Notes outstanding as of December 31, 2015.

Long-Term Financing Obligation

Long-Term Financing Obligation	9 Months Ended
	Dec. 31, 2015
Notes
Long-Term Financing Obligation	12. Long-Term Financing Obligation On December 22, 2011, we entered into an agreement with an independent third-party under which we sold and leased back our land and building generating gross proceeds of $2,000,000. Pursuant to a lease agreement, the initial minimum lease term is 15 years. At the end of the initial minimum lease term, we have the option to renew the lease for three periods of five years each. In addition, we provided, as collateral, a security interest in all furnishings, fixtures and equipment owned and used by us, having a net book value of approximately $0 as of December 31, 2015. For accounting purposes, the provision of such collateral constitutes continuing involvement with the associated property. Due to this continuing involvement, this sale-leaseback transaction is accounted for under the financing method, rather than as a completed sale. Under the financing method, we include the sales proceeds received as a financing obligation. As of December 31, 2015 and March 31, 2015, the total financing obligation was $1,986,000, respectively, and accrued interest on financing obligation was $150,000 and $147,000, respectively. Through December 2018, interest on the financing obligation exceeds the minimum lease payments, accordingly the principal remains constant through that date. After December 2018, the minimum lease payment will exceed interest and principal will be reduced by the excess of minimum lease payment over interest. The building, building improvements and land remain on the condensed balance sheet and the building and building improvements will continue to be depreciated over their remaining useful lives. Payments made under the lease are applied as payments of imputed interest and deemed principal on the underlying financing obligation.

Contingencies

Contingencies	9 Months Ended
	Dec. 31, 2015
Notes
Contingencies	13. Contingencies We are not a party to any legal proceedings, other than ordinary routine litigation incidental to our business, which we believe will not have a material affect on our financial position or results of operations.

Concentrations of Credit Risk a

Concentrations of Credit Risk and Major Customers	9 Months Ended
	Dec. 31, 2015
Notes
Concentrations of Credit Risk and Major Customers	14. Concentrations of Credit Risk and Major Customers For the three months ended December 31, 2015 and 2014, two customers represented 52% of our total revenues and three customers represented 72% of our total revenues, respectively. For the nine months ended December 31, 2015 and 2014, two customers represented 68% of our total revenues and three customers represented 54% of our total revenues, respectively. As of December 31, 2015, we had accounts receivable-trade, net, of $104,000, or 62%, due from two customers. As of March 31, 2015, we had accounts receivable-trade, net, of $133,000, or 62%, due from two customers. As of December 31, 2015, we had $113,000 due from two customers related to receivables on royalties, license and annual usage fees. As of March 31, 2015, we had $76,000 due from two customers related to receivables on royalties, license and annual usage fees. These amounts are classified as accounts receivable-other in the accompanying condensed balance sheets.

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2015
Notes
Subsequent Events	15. Subsequent Events We evaluated all events or transactions that occurred after the balance sheet date through the date when we issued these unaudited condensed financial statements. During this period, we did not have any material recognizable subsequent events.

Interim Financial Statements 20

Interim Financial Statements and Basis of Presentation: Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2015
Policies
Significant Accounting Policies	Our significant accounting policies are described in Note 2 to the financial statements included in Item 8 of our annual report on Form 10-K as of March 31, 2015.

Stock-Based Compensation_ Sched

Stock-Based Compensation: Schedule of Share-Based Compensation Activity (Tables)	9 Months Ended
	Dec. 31, 2015
Tables/Schedules
Schedule of Share-Based Compensation Activity	Options Outstanding Weighted-Average Exercise Price per Share Weighted-Average Remaining Contractual Term in Years Aggregate Intrinsic Value (in thousands) Options outstanding as of April 1, 2015 2,170,750 $ 0.36 $ 190 Granted - - Exercised - - Cancelled or forfeited - - Options outstanding as of December 31, 2015 (unaudited) 2,170,750 $ 0.36 4.71 $ 190 Options exercisable as of December 31, 2015 (unaudited) 2,002,937 $ 0.39 4.46 $ 148 Options vested or expected to vest as of December 31, 2015 (unaudited) 2,170,750 $ 0.36 4.71 $ 190

Inventory_ Schedule of Inventor

Inventory: Schedule of Inventory, Net (Tables)	9 Months Ended
	Dec. 31, 2015
Tables/Schedules
Schedule of Inventory, Net	(in thousands) December 31, 2015 (unaudited) March 31, 2015 Raw materials $ 109 $ 80 Work in progress 39 76 Finished goods 224 278 372 434 Less: allowance for obsolete and excess inventory (130) (130) Total inventories, net $ 242 $ 304

Property, Plant and Equipment23

Property, Plant and Equipment Disclosure: Property, Plant and Equipment (Tables)	9 Months Ended
	Dec. 31, 2015
Tables/Schedules
Property, Plant and Equipment	(in thousands) December 31, 2015 (unaudited) March 31, 2015 Land $ 500 $ 500 Building 2,705 2,705 Machinery, equipment and tooling 1,214 1,214 Furniture, fixtures and office equipment 285 285 Office equipment under capital lease 13 13 4,717 4,717 Less: accumulated depreciation (2,781) (2,719) $ 1,936 $ 1,998

Stock-Based Compensation_ Sch24

Stock-Based Compensation: Schedule of Share-Based Compensation Activity (Details) - Employee Stock Option	9 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance | shares	2,170,750
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.36
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | $	$ 190
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | shares	2,170,750
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ / shares	$ 0.36
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	4 years 8 months 16 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares	2,002,937
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.39
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	4 years 5 months 16 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | $	$ 148
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares	2,170,750
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.36
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	4 years 8 months 16 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | $	$ 190

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Details
Stock-based compensation	$ 2,000	$ 2,000	$ 36,000	$ 9,000

Inventory_ Schedule of Invent26

Inventory: Schedule of Inventory, Net (Details) - USD ($)	Dec. 31, 2015	Mar. 31, 2015
Details
Inventory, Raw Materials, Net of Reserves	$ 109	$ 80
Inventory, Work in Process, Net of Reserves	39	76
Inventory, Finished Goods, Net of Reserves	224	278
Inventory Valuation Reserves	$ (130)	$ (130)

Property, Plant and Equipment27

Property, Plant and Equipment Disclosure: Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2015	Mar. 31, 2015
Details
Land	$ 500	$ 500
Buildings and Improvements, Gross	2,705	2,705
Machinery and Equipment, Gross	1,214	1,214
Furniture and Fixtures, Gross	285	285
Debt and Capital Lease Obligations	13	13
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(2,781)	(2,719)
Property, plant and equipment, net	$ 1,936,000	$ 1,998,000

Property, Plant and Equipment28

Property, Plant and Equipment Disclosure (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Details
Depreciation	$ 14,000	$ 22,000	$ 62,000	$ 105,000

Income (Loss) Per Share (Detail

Income (Loss) Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Details
Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities	$ 3,001,250	$ 2,685,048	$ 1,499,500	$ 2,685,048

Long-Term Financing Obligation

Long-Term Financing Obligation (Details) - USD ($)	Dec. 22, 2011	Dec. 31, 2015	Mar. 31, 2015
Details
Sale Leaseback Transaction, Date	December 22, 2011
Property, plant and equipment, net		$ 1,936,000	$ 1,998,000
Present Value of Future Minimum Lease Payments, Sale Leaseback Transactions		1,986,000	1,986,000
Interest Portion of Minimum Lease Payments, Sale Leaseback Transactions		$ 150,000	$ 147,000

Concentrations of Credit Risk31

Concentrations of Credit Risk and Major Customers (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015
Details
Concentration Risk, Percentage	52.00%	72.00%	68.00%	54.00%
Fair Value, Concentration of Risk, Accounts Receivable	$ 104,000		$ 104,000		$ 133,000
Accrued Fees and Other Revenue Receivable	$ 113,000		$ 113,000		$ 76,000